Cytotoxic T-cell surface key molecule CD4
Cytotoxic T-cell surface key molecule CD4
2023-12-11
Like CD8, CD4 is a transmembrane glycoprotein that acts as a coreceptor for the T cell receptor (TCR) . Like the TCR, CD4 binds to major histocompatibility complex (MHC) molecules ...
Cytotoxic T-cell surface key molecule CD8
Cytotoxic T-cell surface key molecule CD8
2023-12-02
CD8 is a transmembrane glycoprotein that acts as a coreceptor for the T cell receptor (TCR). Like the TCR, CD8 binds to major histocompatibility complex (MHC) molecules but has spe...
SND1: potential prostate cancer target
SND1: potential prostate cancer target
2023-12-01
The most common genetic alteration in human prostate cancer (PC) is a gene fusion involving the androgen-regulated TMPRSS2 gene and the coding sequence of a member of the ETS famil...
T-lymphocyte surface key molecule CD3
T-lymphocyte surface key molecule CD3
2023-11-15
CD3 protein is one of the key molecules in the immune system, involved in activating cytotoxic T cells (CD8+ naive T cells) and T helper cells (CD4+ naive T cells), responsible for...
Polygenic proinflammatory cytokine IL6
Polygenic proinflammatory cytokine IL6
2023-11-09
Interleukin-6 is a multifactorial proinflammatory cytokine, a hemoglobin complex composed of IL-6, its receptor IL6R, and glycoprotein 130 (IL-6/ILL-6R/GP130). This complex complex...
The advent of the era of antibody coupled drug ADC
The advent of the era of antibody coupled drug ADC
2023-06-21
Over the past 30 years, antibody-based anti-cancer therapies have achieved considerable success. Antibody-drug conjugates ( ADCs), a complex and evolving class of drugs, are specif...
Literature share antibody sequences defined a new target for osteosarcoma CAR-T therapy
Literature share antibody sequences defined a new target for osteosarcoma CAR-T therapy
2023-06-13
Osteosarcoma (OS) remains a frustrating malignancy in children and young adults, with a dismal prognosis for metastatic and recurrent disease. Immunotherapy in OS is less promising...